This study investigates if a combination of two drugs, **T-DM1** and **tucatinib**, can better prevent the return of **HER2-positive breast cancer** than T-DM1 alone. T-DM1 combines a targeted therapy, trastuzumab, with a chemotherapy drug, DM1. Trastuzumab targets specific cancer cell markers called HER2 receptors. Tucatinib is a drug that may block certain enzymes to stop cancer cell growth. Patients will receive treatments every 21 days for up to 14 cycles unless the disease progresses or severe side effects occur. After treatment, participants are monitored for up to 10 years.
- Participants may need to visit the clinic every 21 days for treatments.
- The trial includes follow-up visits for 10 years to monitor health.
- Potential side effects may occur; discuss risks with your doctor.
How understandable was the trial content above?
Hard to understand
Easy to understand